136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. (Q51521616)
Jump to navigation
Jump to search
scientific article published on 15 April 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. |
scientific article published on 15 April 2016 |
Statements
136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. (English)
1 reference
M-J Ahn
1 reference
J Yang
1 reference
H Yu
1 reference
H Saka
1 reference
S Ramalingam
1 reference
K Goto
1 reference
S-W Kim
1 reference
L Yang
1 reference
A Walding
1 reference
G R Oxnard
1 reference
15 April 2016
1 reference
11
1 reference
4 Suppl
1 reference
S115
1 reference